

United States Marine Corps
Human Research Protection Program
Policy and Procedures



30 September 2013

Reviewed by:
Leah B. Watson
Chair, USMC Institutional Review Board

Approved/Released for Publication by:


J.W. BEAROR
USMC Institutional Official

Contents

Chapter 1: Introduction.....	1-1
1.1 Background.....	1-1
1.2 Assurance Requirement.....	1-1
1.3 Human Participant versus Human Subject.....	1-1
1.4 Conflicting Regulations.....	1-1
1.5 International Research.....	1-2
1.6 Classified Research.....	1-2
1.7 Public Release of Research Information.....	1-2
1.8 Federal Funds.....	1-2
1.9 Compensation.....	1-2
1.10 Vulnerability and Additional Protections.....	1-2
1.11 Captured or Detained Personnel.....	1-2
1.12 Survey Research.....	1-3
1.13 Contracting Clause.....	1-3
Chapter 2: Guiding Principles.....	2-1
Chapter 3: Authority and Delegation.....	3-1
Chapter 4: Institutional Official and IRB Roles and Responsibilities.....	4-1
4.1 Institutional Official.....	4-1
4.2 Chair, IRB.....	4-3
4.3 Vice-Chair, IRB.....	4-4
4.4 Administrator, IRB.....	4-5
4.5 Member, IRB.....	4-5
4.6 Human Research Protection Official.....	4-6
4.7 Scientific Reviewer.....	4-6
4.8 Research Monitors and Ombudsmen.....	4-6
Chapter 5: Principal Investigator Roles, Responsibilities, and Process Guidance.....	5-1
5.1 General Roles and Responsibilities.....	5-1
5.2 Process Guidance.....	5-2
Chapter 6: Education and Training.....	6-1
Chapter 7: IRB Membership Requirements.....	7-1
Chapter 8: IRB Functions and Operations.....	8-1
Chapter 9: Project Review Process.....	9-1
9.1 Determination of Human Subjects Research.....	9-1
9.2 Protocol Package Submission.....	9-1
9.3 IRB Chair and Vice-Chair Preliminary Review.....	9-1
9.4 Convened IRB Review.....	9-2
9.5 USMC IO Review Package.....	9-3

Contents (cont.)

9.6	USMC IO Approval Authority	9-3
9.7	DON HRPP Review.....	9-3
Chapter 10: IRB Protocol Submission Package for Human Subjects Research.....		10-1
Chapter 11: Greater Than Minimal Risk		11-1
Chapter 12: Research That Meets Criteria For Exemption.....		12-1
Chapter 13: Expedited Review Process		13-1
13.1	Expedited Review Categories	13-1
13.2	Expedited Review Criteria.....	13-1
Chapter 14: Criteria for Approval of Research.....		14-1
Chapter 15: Informed Consent.....		15-1
15.1	General Informed Consent Requirements.....	15-1
15.2	Required Elements of Informed Consent.....	15-2
Chapter 16: Continuing Review and Reporting Requirements.....		16-1
Chapter 17: Scientific Review		17-1
Chapter 18: Non-compliance, Misconduct, Adverse Events, Unanticipated Problems		18-1
18.1	Allegations of Non-compliance with Human Subject Protections	18-1
18.2	Allegations of Research Misconduct	18-1
18.3	Unanticipated Problems Involving Risk to Subjects or Others (UPIRTSO)	18-1
18.4	Serious Adverse Events	18-2
18.5	Unanticipated Problems	18-2
18.6	Summary Reporting	18-2
Chapter 19: IRB Review Requirements for External DoD Institutions.....		19-1
Chapter 20: Extramural Human Subject Research		20-1
Chapter 21: Collaborative Research		21-1
21.1	Collaborative Research with Another DoD/DON Institution.....	21-1
21.2	Collaborative Research with a Non-DoD Institution.....	21-1
21.3	Collaborative Effort with an Associate Investigator Not Affiliated with the Marine Corps	21-2

References

Figures

Figure 3-1. Authority Delegation and Communication Flow within the HRPP	3-2
Figure 9-1. IRB Review Process.....	9-4
Figure 19-1. IRB Review Process for External Performance Sites	19-1

Appendices

Appendix A: Categories of Exemption.....	A-1
Appendix B: Expedited Review Categories	B-1
Appendix C: IRB Action Request.....	C-1
Appendix D: Full Protocol.....	D-1
Appendix E: Investigator Affirmation	E-1
Appendix F: Continuing Review Report	F-1
Appendix G: Project Completion Report.....	G-1
Appendix H: Adverse Event Report	H-1
Appendix I: Documentation Checklist for Investigators, IRB, and DON HRPP	I-1
Appendix J: Abbreviations, Acronyms and Initialisms	J-1
Appendix K: Definitions.....	K-1

Chapter 1: Introduction

1.1 Background

The protection of the rights and welfare of research volunteers is an acknowledged and accepted Command responsibility. This document details United States Marine Corps (USMC) specific procedures to ensure the protection of human subjects as stated in references (a) through (e) and based on the ethical principles described in reference (f). Constructive communication and dialog among all parties involved in the review and conduct of research involving human subjects is encouraged as a means of maintaining an awareness of the importance of safeguarding the rights and welfare of human subjects.

1.2 Assurance Requirement

Human subjects research covered by this document shall be performed only by institutions or activities holding an appropriate institutional assurance of compliance from a Department of Defense (DoD) assurance approval authority. The Navy Surgeon General (SG) holds the Department of Navy (DON) assurance approval authority for new assurances, renewal of current assurances, and acceptance of other assurances. Key requirements of the DoD-Navy Assurance are completion of research ethics training, designation of an Institutional Review Board (IRB) to review research protocols, and the institution's plan for monitoring its human subjects research. Human subjects research shall not be initiated until the institution holds a valid assurance for the protection of human research subjects, the research protocol has been reviewed by an authorized IRB, and approval granted by an appropriate research approval authority.

1.3 Human Participant versus Human Subject

Human subjects research is clearly defined in references (b), (c), and (d). In support of its mission, the Marine Corps carries out research activities that involve human participants. Research with human *participation* does not necessarily constitute human subjects research. Human participation requires safety involvement to ensure the safety of participants, but may not require involvement of the IRB for human subject's protection.

1.4 Conflicting Regulations

Issues pertaining to the protection of human subjects are constantly evolving, and there may at times be conflicts between applicable regulations. References (a) through (c) carry the force of law and supersede all other administrative regulations. In all cases, the regulation, instruction, or policy providing the greatest protection for the human subject shall prevail. Questions about resolving conflicts should be directed to the DON Human Research Protection Program (HRPP).

1.5 International Research

Research involving human subjects who are not U.S. citizens or DoD personnel, conducted outside the United States, and its territories and possessions, requires permission of the host

country. The laws, customs and practices of the host country and those required in references (d) and (e) shall be followed.

1.6 Classified Research

Classified research with human subjects is held to the same ethical principles and human subject protections as unclassified research and must receive prior approval from the Secretary of Defense (SECDEF) in accordance with reference (g). Classified research is not eligible for review under expedited review procedures as noted in reference (h).

1.7 Public Release of Research Information

To foster public trust in research and human subject protections, information is made available to the public, the news media, and Congress. This information may be released after appropriate review and approval per references (i), (j), and other applicable guidance.

1.8 Federal Funds

Federal funds administered by a department or agency may not be expended for research involving human subjects unless the requirements of references (c) and (d) have been satisfied.

1.9 Compensation

Civilians and military personnel not in a duty status (e.g., normal off duty hours, reservists not on active duty, etc.) may be compensated for participation in research studies, but the compensation or any other incentive must not be extraordinary to eliminate possible undue influence of volunteers. Federal personnel (civil servants or service members) participating as human subjects in DoD conducted research while on duty (i.e., not on leave and participating during their duty hours) may be compensated per reference (d).

1.10 Vulnerability and Additional Protections

Additional safeguards shall be provided for subjects who may be considered vulnerable to coercion or undue influence because of their age, health, employment, financial status, or other circumstances. References (c) and (d) require additional safeguards for prisoners, pregnant women, mentally disabled individuals, economically, or educationally disadvantaged individuals. Other groups warranting additional protection include severely ill patients, those in employer-employee status (worker), student-teacher, supervisor-subordinate relationships, or deployed active duty personnel. Service members and their status as adults, for the purposes of legal capacity to participate in DoD-conducted or DoD-supported research involving human subjects, is addressed in reference (d). Regardless of the risk level of the research, no seniors shall influence the decisions of their subordinates whether to participate as research subjects.

1.11 Captured or Detained Personnel

Research involving any person captured, detained, held, or otherwise under the control of DoD personnel (military, government civilian, or contractor) is prohibited. Such persons include:

Enemy Prisoners of War, Civilian Internees, Retained Persons, Lawful and Unlawful Enemy Combatants. Such persons do not include DoD personnel being held for law enforcement purposes. Refer to references (c), (d), and (k) for regulations.

1.12 Survey Research

Surveys, other than those executed entirely within the command, require survey review and approval, per reference (l). The Marine Corps Survey Approval Manager (if appointed) may require IRB review of the survey instrument prior to granting approval.

1.13 Contracting Clause

Defense Federal Acquisition Regulation System (DFARS) policy has been revised to address statutory and regulatory requirements for the ethical treatment of human subjects involved in research projects. Clauses for use in contracts involving human subjects in research were issued in 29 July 2009 to inform contractors of their responsibilities for compliance with references (a), (b) and (d); applicable DoD component policies, and when applicable Food and Drug Administration policies and regulations. Title 38, Code of Federal regulations Part 207, Acquisition Planning; Part 235, Research and Development Contracting ; and Part 252, solicitation Provisions and Contract Clauses were amended. Reference (r) requires a DoD component sponsoring research involving human subjects must have a Human Research Protection Official (HRPO). The HRPO will be identified in the DoD component's Human research Protection Management Plan and shall be identified in acquisition planning. Refer to reference (r) for specific contractual language and clauses.

Chapter 2: Guiding Principles

The Marine Corps supports the ethical principles outlined in the Belmont Report (reference (f)), and listed below, as the foundation for its human research.

- a. **Respect for Persons.** Respect for persons incorporates at least two ethical convictions: first, individuals should be treated as autonomous agents; and second, persons with diminished autonomy are entitled to protection.
- b. **Beneficence.** Beneficence involves two general rules: (1) Do not harm, and (2) Maximize possible benefits and minimize possible harms.
- c. **Justice.** Justice requires that people are treated fairly; burdens and benefits are shared equitably. Subjects must be selected equitably, and vulnerable populations and populations of convenience must not be exploited.

Chapter 3: Authority and Delegation

- a. In accordance with reference (e), the Secretary of the Navy delegates the authority and responsibility for the DON HRPP to the Navy Surgeon General (SG), except for those specifically retained by the Secretary of the Navy and those delegated to the Under Secretary of the Navy.
- b. The Navy SG may delegate to Commanders, Commanding Officers, and Officers in Charge the authority to approve human subjects research protocols under their respective cognizance through an approved DoD-Navy Assurance for the Protection of Human Research Subjects. The Institutional Official (IO) can also serve as a Commander.
- c. The IO may delegate to the IRB Chair and Vice Chair authority to review and make recommendations for research that is eligible for expedited review, and to suspend research due to adverse events involving subjects or others, significant deviation from approved protocols, or for reasonable cause.
- d. This authority may not be further delegated.

Figure 3-1 illustrates the authority delegation for the DON HRPP. In addition, the figure shows the communication flow between the DON HRPP, the Marine Corps IO, the IRB, and research personnel.




Figure 3-1. Authority Delegation and Communication Flow within the HRPP

Chapter 4: Institutional Official and IRB Roles and Responsibilities

All Navy and Marine Corps personnel conducting, supporting, reviewing, approving, or managing human subjects research shall view the protection of human subjects as an important command issue at all echelons, both ashore and afloat. Commanders, Commanding Officers, Officers in Charge, Institutional Officials, heads of activities, scientific and technical program managers, project directors, IRB members, IRB support staff, and investigators shall maintain concern for the safety and welfare of volunteer subjects.

4.1 Institutional Official

The Executive Deputy, Training and Education Command (TECOM) serves as the Institutional Official (IO) for the Marine Corps. The Marine Corps IO has overall responsibility for the conduct of the Marine Corps HRPP for all Marine Corps commands and organizations not having their own Institutional Assurance.

The IO shall:

1. Complete and document initial and continuing research ethics and human subject protections training.
2. Appoint in writing the IRB Chair, Vice-Chair, and members
3. Serve as their institution's research approval authority contingent upon holding that delegated authority.
4. Ensure that subjects' decisions to participate are voluntary and are protected from undue influence.
5. Verify, for each research protocol, whether their institution is engaged in human subjects research as determined by the IRB. Require certification (IRB approval) from the performing activity or activities before allowing the research to begin.
6. Obtain a DoD-Navy Assurance from the Navy SG and:
 - a. Obtain a Federal-wide Assurance (FWA) when the institution is engaged in other than DoD supported research.
 - b. Verify that all engaged collaborating institutions for human subjects research, domestic and international, hold a valid DoD, DON, or other federal assurance with DoD-Navy Addendum.
 - c. Submit an updated assurance whenever the IO or IRB Chair changes.
7. Ensure an independent review of research for scientific merit prior to IRB review.

-
8. Ensure that research protocols are reviewed and evaluated by the IRB in strict compliance with all elements of pertinent laws, regulations, and guidance, in an expeditious and timely manner.
 9. Approve research protocols only after IRB review and recommendation for approval.
 10. Approve research protocols only after review and recommendation for approval by IRB Chair or Vice Chair(s) for research that meets criteria for expedited review.
 11. Approve, require modifications to gain approval, disapprove new research protocols; require additional safe-guards, or refer the protocol to a higher approval authority, after reviewing and considering, at a minimum, the minutes of IRB meetings or the IRB Chair's written recommendations for research eligible for expedited review.
 12. Approve, require modifications to gain approval, or disapprove continuation of current research protocols; require additional safeguards, suspend or terminate the research based on specific criteria and the IRB's continuing review findings or the IRB Chair's written recommendations for research eligible for expedited review.
 13. Adhere to or increase the safeguards or special conditions recommended by the IRB.
 14. Support IRB recommendations when research protocols are recommended for disapproval.
 15. Review exemption recommendations made by the IRB and where appropriate, require review of a protocol that the IRB has determined to meet criteria for exemption.
 16. Refer research protocols for which the IO is also an investigator or member of the research team to a higher research approval authority for review.
 17. Provide certifications of research protocol review and approval to funding organizations, sponsors, and collaborators.
 18. Submit all research protocols and supporting documentation for Navy SG headquarters-level administrative review.
 19. Maintain appropriate research records in a retrievable format as "Project Case Files" as required by reference (m).
 20. Allocate resources adequate to ensure compliance with the institution's assurance and all applicable guidance.
 21. Negotiate appropriate written agreements with participating institution(s) for cooperative/collaborative research projects per Chapter 19 of this document. Obtain endorsement from the Director, DON HRPP for agreements relying on IRBs established under other assurances or relying on independent IRBs.

-
22. Review and, if applicable, take action on any allegations of non-compliance with human subject protections or allegations of research misconduct [reference (n)].
 23. Suspend research due to adverse events involving subjects or others, significant deviation from approved protocols, or for reasonable cause.
 24. In accordance with reference (e), forward all protocols that require higher approval authority to the Navy SG via DON HRPP.
 25. Report the following to the DON HRPP and appropriate sponsor(s):
 - a. Unanticipated problems involving risks to subjects or others (UPIRTSO), or serious adverse events.
 - b. All suspensions or terminations of previously approved research protocols.
 - c. The initiation and results of all investigations of non-compliance with human subject protections and the investigations and results of research misconduct, regardless of the findings.
 - d. All audits, investigations, or inspections of Marine Corps-supported research protocol and the institution's HRPP conducted by an outside entity.
 - e. Significant communication between the institutions conducting research and other federal departments and agencies regarding compliance and oversight.
 26. Provide space for IRB meeting and staff.
 27. Ensure annual review of HRPP policy and procedures.

4.2 Chair, IRB

1. Serve as a source of information concerning human subjects research policies.
2. Complete and document initial and continuing research ethics and human subject protections training.
3. Conduct preliminary reviews to determine:
 - a. Whether the proposed study meets the definition of research as defined in reference (b).
 - b. Whether the proposed study meets the definition of human subjects research as defined in reference (b) and (d).
 - c. The level of research risk associated with protocols.
 - d. Whether a protocol meets criteria for exemption.

-
- e. Whether a protocol meets criteria for expedited review.
 4. Review and make recommendations on research protocols that meet criteria for expedited review procedures.
 5. Conduct concurrence determination of human subjects research, or delegates to Vice-Chair.
 6. Monitor continuing human subjects research for protocol changes.
 7. Suspend research due to an UPIRTSO, , or serious adverse events, significant deviation from approved protocols, or for reasonable cause.
 8. Assign research protocols to appropriate reviewers.
 9. Periodically brief the IO on the status of IRB activity and active protocols.
 10. Ensure the IRB is informed of all ongoing human subjects research.
 11. Determine whether the proposed research meets criteria for exemption, expedited review or convened IRB review procedures. These and all other determinations are subject to subsequent review and endorsement by the convened IRB.

4.3 Vice-Chair, IRB

1. Serve as IRB Chair in the absence of the Chair.
2. May serve as the IRB administrator.
3. When assigned by or acting as Chair, conduct preliminary reviews to determine:
 - a. Whether the proposed study meets the definition of research as defined in reference (b).
 - b. Whether the proposed study meets the definition of human subjects research as defined in references (b) and (d).
 - c. The level of research risk associated with protocols.
 - d. Whether a protocol meets criteria for exemption.
 - e. Whether a protocol meets criteria for expedited review.
4. Complete and document initial and continuing research ethics and human subject protections training.
5. When appropriate conduct concurrence determination of human subjects research.

4.4 Administrator, IRB

1. Maintain a log of all submissions to the IRB, assigning a formal tracking number to each research protocol and tracking each protocol through the review process.
2. Maintain documentation of all HRPP determinations of human subjects research to present to a convened IRB.
3. Complete and document initial and continuing research ethics and human subject protections training.
4. Monitor the approval period of protocols, schedules reviews, and notifies the IRB Chair and Principal Investigator (PI) of protocol certifications about to expire.
5. Take minutes of the convened IRB meetings.
6. Retain records in accordance with the checklist in Appendix I.
7. Retain all documentation as prescribed in reference (m).
8. Forward all required documentation to DON HRPP in format specified by DON HRPP.
9. Serve as HRPP Point of Contact (POC) for training and communication.
10. Submit updates to DON HRPP when there are changes to the Institutional Official, IRB Chair, Vice Chair(s), and members, or, when changes are made to documents supporting the Institutional Assurance.
11. Conduct an administrative overview, at least annually to ensure effectiveness of IRB policies and procedures.
12. Assist in the execution of Individual Investigator Agreements (IIA) and Institutional Agreements for IRB Review (IAIR), when required.

4.5 Member, IRB

1. Unless another HRPP POC has been designated by an Institutional Assurance, serve as their organization's primary HRPP POC.
2. Complete and document initial and continuing research ethics and human subject protections training.
3. For research originating within their organization, or when appropriate, conduct initial HRPP review to determine if protocol meets the definition of Human Subjects Research with concurrence from the IRB Chair or Vice-Chair.
4. Ensure that PIs within their organization, submit protocols that meet the definition of Human Subjects Research to the IRB Administrator for coordination an initial review.

4.5 Human Research Protection Official (HRPO)

1. Complete the required initial and ongoing research ethics training, including human subject protection training.
2. Review the Assurance of compliance and IRB approval submitted by the contractor and verify that the Assurance is appropriate for the research as stated in the Statement of Work.
3. Review the protocol and accept the contractor's IRB approval for compliance with DoD, DON and Marine Corps policies.
4. Confirm that the contractor's determination that the proposed research is not research involving human subjects.
5. Confirm that the contractor's determination that the proposed research meets an exemption criteria in 32 CFR 219.101(b) is correct.
6. Notify the Contracting Officer of all human subject research determinations.

4.6 Scientific Reviewers

1. Complete required initial and ongoing research ethics training including human subject protection training.
2. Review each assigned human subject protocol application for scientific merit or scholarship per the Marine Corps standards as established in this policy and procedures manual or by other standing operating procedure (SOP) for scientific review before forwarding it for IRB review.

4.7 Research Monitors and Ombudsmen

1. Complete required initial and ongoing research ethics training including human subject protection training.

Chapter 5: Principal Investigator Roles, Responsibilities, and Process Guidance

The human subjects research PI has primary responsibility for compliance with all human subject protection regulations, directives, and instructions. PIs for Marine Corps sponsored research must be current federal employees. The IRB does not recognize Co-PIs, a single PI must be listed on the protocol submission. PIs must be employees of the U.S. Federal Government; as such, they must be either uniformed service members or Federal civilian employees. Contractors are not permitted to serve as PIs.

5.1 Guidelines for Investigators

PIs shall:

1. Complete and document initial and continuing research ethics and human subject protections training.
2. Obtain institutional approval prior to conducting or continuing research, and prior to implementing proposed amendments to approved research.
3. Obtain written determination of whether the proposed activity is human subjects research or the research meets criteria for exemption per reference (b).
4. Ensure that human subjects projects have been independently scientifically reviewed prior to submission to the convened IRB for review.
5. Notify the IRB in writing of: UPIRTSOs; serious adverse events; non-compliance with the human subject protection regulations or IRB requirements; and protocol deviations.
6. Obtain and document informed consent from research subjects, unless the IRB approves a waiver or alteration of the informed consent process per reference (b), and provide subjects a copy of the completed informed consent document prior to the start of research.
7. Retain records in accordance with Appendix I to verify compliance with reference (b).
8. Ensure that all human subjects used are properly qualified, informed, briefed, and prepared prior to exposure to research risk.
9. Ensure that all associate investigators are covered by a DoD or Federal Assurance, educated in all phases of research, including the recruitment of subjects, obtaining informed consent, providing necessary reports, and maintaining study documents.
10. Ensure all associate investigators complete and document initial and continuing research ethics and human subject protections training.

-
11. Suspend or terminate exposure of human subjects to research risks whenever indicated to protect the subject.
 12. Obtain institutional approval prior to implementing amendments to the previously approved research project.
 13. Upon completion of the approved research project, submit a final project report stating completion status.
 14. PI's, internal and external to the Marine Corps must obtain written support/non-support of a protocol from the local Marine Corps command(s) where the protocol is intended to be conducted. The local Commander's support for the protocol must be obtained or endorsed at the Lieutenant Colonel (O-5) or Colonel (O-6) level. Local command support/non-support of a protocol doesn't constitute Marine Corps institutional approval/disapproval of the protocol.

5.2. Process Guidance

The following section is provided to give a brief overview of the entire review process and provide a quick reference for PIs to find applicable chapters, sections and forms.

5.2.1. Human Subjects Research Review

In order to determine if a specific project meets the definition of human subjects research (as defined at 32 CFR 219), the PI shall contact the IRB Administrator or their organization's IRB Vice-Chair to initiate an applicability review. For details, see section 9.1 (Determination of Human Subjects Research).

5.2.2. Initial Protocol Submission

If a project is determined to meet the definition of human subjects research as required in Paragraph 5.2.1, the PI shall prepare protocols that fully describe the proposed research. To do so, the PI shall submit an IRB Action Request (Appendix C), Full Protocol (Appendix D), Investigator Affirmation (Appendix E), and other supporting documentation as outlined in Chapter 10. Protocols must be submitted no later than 14 days prior to scheduled IRB meeting to allow sufficient time for review, in the event that the protocol requires review by the convened board. PIs should consult with the IRB Chair or Administrator for the current calendar of scheduled IRB meetings. Protocols which do not meet this submission deadline will be reviewed and the following month's IRB meeting. The IRB Action Request serves as a declaration of accuracy and completeness. The PI's supervisor will sign an endorsement of scientific soundness, based on a complete scientific review of the protocol per the Marine Corps scientific review guidance contained in this Policy and Procedure. The supervisor will not conduct the scientific review, but will indicate, by their signature, that the scientific review was conducted and acknowledging that the research is supported within the submitting organization. The PI will submit the protocol, with the proof of scientific review, to the IRB Administrator. See Chapter 9 for review details. Additional requirements for greater than minimal risk protocols are found in Chapter 11.

5.2.3. Protocol Modification

For modifications to approved research protocols, the PI shall submit an IRB Action Request (Appendix C) and other supporting documentation indicating changes requested. If the PI is unsure of whether the changes require submission of an IRB Action Request, the IRB Chair or Vice-Chair should be consulted. The PI must obtain institutional approval prior to implementing proposed modifications to the approved research protocol. In general, the PI is only authorized to make stylistic changes (e.g., font type, formatting, etc.) to an approved protocol. Changes to approved members of the research team, protocol language, process, technique, procedure, population etc., must be reviewed by the IRB.

5.2.4. Continuing Review

When a protocol is scheduled for a continuing review, the PI shall submit an IRB Action Request (Appendix C), a Continuing Review report (Appendix F), and any supporting documentation (latest informed consent document, copies of adverse event reports). See Chapter 16 for more information.

5.2.5. Project Completion Report

Upon completion of a research project, the PI shall submit an IRB Action Request (Appendix C), Project Completion Report (Appendix G), and any published book, book chapter, journal article, technical report, or technical note about the project. Additionally, any presentations or briefs should also be submitted as part of the Project Completion Report.

5.2.6. Unanticipated Problems, UPIRTSOs and Serious Adverse Events

In the event of an unanticipated problem (protocol deviation, adverse event, UPIRTSO) or serious adverse event, the PI shall submit an IRB Action Request (Appendix C), Unanticipated Problem or Serious Adverse Event Report (Appendix H), and any other supporting documentation.

- a. Serious adverse events are to be reported (at least verbally or via e-mail) to the supervisor and IRB Chair or Vice-Chair immediately. The PI shall follow up with a written Unanticipated Problem or Serious Adverse Event Report within 24 hours of discovery of event. See Chapter 18 for additional information.
- b. Written reports of unanticipated problems shall be submitted to the Chair or Vice-Chair via the IRB Administrator within 15 days. See Chapter 18 for additional information.
- c. Summaries of unanticipated problem or serious adverse event experiences will be submitted with each Continuing Review Report and Project Completion Report.

5.2.7 PI Recourse for Disapproved Protocols

The PI may revise and submit a disapproved protocol as a new protocol.

Chapter 6: Education and Training

Per references (d), (e), (u), (s) and DON HRPP Training and Education Guidance, all personnel who conduct, review, approve, support, manage, or oversee DON-supported human subject research are required to complete initial and continuing research ethics training appropriate to their roles and responsibilities. This includes the IO, all IRB members, HRPO(s), all PIs, associate investigators, and support personnel directly involved in research. This also includes personnel selected as local Marine Corps command advisors to research teams. Personnel will complete their required training before assuming their DON human research protection duties. Required training shall be repeated at least every three years. The IRB Administrator is the HRPP training POC and will maintain a record of all required HRP training certificates. For those commands/organizations with their own Institutional Assurance, the HRP Point of Contact at that institution will ensure that individuals with a role in Human Subject Research complete the appropriate training and provide a copy of the completion certificate to the IRB Administrator.

Chapter 7: IRB Membership Requirements

The role of the Marine Corps IRB is to ensure the safety and welfare of human subjects in research. The IRB is charged with ensuring compliance with mandated policies and procedures through the application of sound judgment regarding the relative benefits versus risks associated with each specific research effort.

- a. **General Overview.** The IRB coordinates all activities related to the protection of human subjects, ensuring that proper procedures are in place for safe conduct of research through a review of documents, inspections, and observation. Sufficient dialogue between the PI and IRB members, and among IRB members, should occur to provide the board with sufficient understanding of the research so that they can properly appreciate the risks and benefits involved.
- b. **Composition of the IRB.** The IRB members must be current federal employees or individuals appointed under the Intergovernmental Personnel Act (IPA). Consultants may be used if a specific relating to proposed research is required by the Board (e.g., an exercise physiologist may be used in research related to physical fitness). The IRB shall have at least five members, of varying backgrounds in accordance with reference (b), in order to promote complete and adequate review of varied research activities, and shall be sufficiently qualified through experience and expertise to fulfill their obligations.
 1. The voting members of the IRB will consist of personnel either from the marine Corps or invited board membership through agreement. The IO may appoint additional voting members to meet requirements.
 2. Alternate members of the IRB may be appointed by the IO to share the responsibilities of IRB membership. Attendance of alternate members may be requested by the IRB Chair or Administrator for convened IRB meetings to establish a quorum for voting.
 3. The IRB shall not consist entirely of men or women.
 4. The IRB shall not consist entirely of members of one profession.
 5. The IRB shall include at least one member from a scientific area, and at least one from a non-scientific area.
 6. The IRB shall include at least one member who is not otherwise affiliated with the Marine Corps and who is not an immediate family member of a person who is affiliated with the Marine Corps.
 7. The IRB Chair is designated in writing by the IO.
 8. The Chair shall be appointed for a one-year term. Unless a different appointment is made by the IO, the term shall be automatically renewed. Once appointed by the

IO, the Chair may only be removed by a majority vote at a convened meeting of the IRB.

9. The IRB Chair or Vice-Chair may serve as the administrator for the IRB.
10. All IRB members must be free of any conflict of interest (COI) with any protocol that he or she reviews. IRB members are required to recuse themselves from IRB discussions and/or voting when any known COI exists.
11. The IO shall not be a member of the IRB.
12. Members shall serve a two-year term. They may serve consecutive terms, with no term limit. Unless a different appointment is made by the IO, the term shall be automatically renewed.
13. The IRB may invite individuals with competence in special areas to assist in the review of issues as ad hoc members. These individuals may be excluded from deliberations and shall neither vote nor be counted when determining the presence of a quorum.
14. If classified research is reviewed, each reviewing IRB member must hold an appropriate security clearance and have been granted access.

- c. **Conflict of Interest.** Conflict of interest is defined as any situation in which professional, financial, or personal interests may compromise or present the appearance of compromising an individual's or group's judgment in conducting, reviewing, approving, managing, and supporting research. Any investigators, key research personnel, IRB members, or other personnel must disclose all conflicts of interest, including any financial interests for themselves, spouses, and dependent children. No person shall be involved in any review or approval of a protocol when there may be a conflict of interest. If the IRB Chair or the IO is involved in a research protocol and a conflict of interest exists, these individuals may not review or approve the research. The next higher echelon in the HRPP approval authority chain of command must review the research protocol.

Chapter 8: IRB Functions and Operations

The primary role of the Marine Corps IRB is to ensure the safety and welfare of human research subjects. The Marine Corps IRB makes recommendations for research protocols to the Marine Corps IO or other IOs supported by IAIRs.

1. The IRB shall ensure that in every project or task in which human subjects are involved:
 - a. The rights and welfare of the subjects are adequately protected.
 - b. The risks to subjects are outweighed by the potential benefits and by the importance of the knowledge to be gained.
 - c. Informed consent of the subjects is obtained by methods that are adequate and appropriate as required by reference (b).
 - d. The applicability of these regulations to any research proposal involving human subjects is determined.
 - e. The level of risk involved is determined based on the definitions in reference (b), and sound professional judgment.
2. Except when an expedited review procedure is used, proposed research shall be reviewed at convened meetings at which a quorum of the IRB is present. A quorum is defined as more than half of the Marine Corps IRB membership. For example, if the IRB has a total of 11 committee positions, it takes 6 members to make a quorum. In order for the research to be approved, it shall receive the approval of a majority of those members present at the meeting. Should the quorum fail during a meeting (i.e., loss of a majority through recusal of members with conflicting interests or early departures, or absence of a nonscientist member), the IRB may not take further actions or votes unless the quorum can be restored.
3. The convened IRB shall meet and conduct reviews for all projects identified by the IRB Chair as involving either greater than minimal risk or minimal risk but determined to not meet criteria for exemption and ineligible for expedited review. Each member may have only one vote; alternates may only vote in the absence of the primary member. The votes of individual members shall not be recorded by name, but only as an anonymous total: For, Against, or Abstaining. A majority vote shall decide any motion. However, a dissenting member may attach an anonymous opinion to the board's recommendation for consideration by the IO.
4. The convened IRB shall meet quarterly or as needed. A meeting may be conducted outside regularly scheduled times at the request of the IO, IRB Chair, or IRB member.
5. The IRB shall conduct reviews in accordance with procedures outlined in Chapter 9.

-
- a. For research at all levels of risk, the IRB shall apply the criteria in Chapter 14 and forward written recommendations to the IO.
 - b. If the level of research risk is determined to be greater than minimal risk, the IRB shall also ensure that the specific additional requirements listed in Chapter 11 are met.
6. The IRB Chair, or designate, shall notify the PIs of the IO's actions or recommendations.
 7. The IRB shall conduct continuing reviews of all approved research in accordance with Chapter 16.
 8. The IRB Chair shall maintain adequate documentation of its activities permanently, in accordance with Appendix I. Required documentation includes:
 - a. Approved DoD-Navy assurance for the IO to approve human subject research studies conducted under the jurisdiction of the Marine Corps.
 - b. Copies of all official correspondence.
 - c. A list of the current roster of IRB members identified by name and including: business address and telephone number, earned degrees, and indications of experience (such as board certifications, licenses, curriculum vitae, etc., or a statement of qualification for non-professional members) sufficient to describe each member's qualifications and anticipated contributions, any relationship between the member and the Marine Corps (for example, employee, family member of employee, paid consultant, etc.), and representative capacity on the board.
 - d. Samples of model documents, correspondence, and consent forms.
 - e. Written procedures for the IRB not included in this instruction.
 - f. Written minutes of IRB meetings, which shall include attendance at the meetings; actions taken by the IRB and the anonymous summary vote on these actions; summary of discussions, including the logical basis for requiring changes in or recommending disapproval of proposed research; and all anonymous dissenting opinions added to the record.
 - g. Institutional Agreements for IRB Review (IAIR), Individual Investigator Agreements (IIAs) and any other agreement related to review or conduct of human subjects research.

Chapter 9: Project Review Process

IRB review and Institutional approval of human subjects research is required prior to recruiting and enrolling subjects, analyzing data, conducting research interventions, or preparing publications or presentations. The Project Review Process is depicted in Figure 9-1. Figure 9-1 is not intended to represent every scenario (for example, if the IO is a subject in the research), but will be applicable to a majority of protocols.

9.1 Determination of Human Subjects Research

The PI coordinates an HRPP review for determining whether the work meets the definitions of research and human subjects with the IRB Administrator who notifies the IRB Chair/Vice-Chair for determination whether reference (b) applies to a project. This review is referred to as an HRPP applicability review. Proposals submitted for applicability review may use the format in Appendix D, but must provide sufficient information to enable the Chair and Vice-Chair to make an informed determination as to whether the study meets the definitions of human subjects research. This will normally include who is sponsoring the study, who is conducting the study, the purpose of the study or data collection, what the study will involve, the intended subjects or participants, and who the results of the study will be shared with. The IRB Chair can make this determination or can defer to the IRB Vice-Chair if better suited to review the project based on experience. The IRB Chair can review SOPs, Test Plans, or general protocols. The determination of whether the project does or does not meet the definition of human subjects research must then receive concurrence from the IRB Chair and a Vice-Chair. If a determination of "not human subjects research" is made, the IRB Chair sends a memo to the PI documenting the decision. Projects that are deemed to meet the definition of human subjects research must then submit a full protocol to the IRB Administrator.

9.2 Protocol Package Submission

If the project is determined to meet the definition of human subjects research, the PI must submit a protocol package to the IRB Administrator. Protocol requirements are found in Chapter 10. The IRB Administrator receives protocol packages from PIs, checks the packages for completeness, assigns a protocol number and keeps the protocol packages and supporting documentation on file for the IRB. The IRB Administrator tracks research protocols and requests through the review process.

9.3 IRB Chair and Vice-Chair Preliminary Review

The IRB Chair and Vice-Chair, conduct preliminary reviews of submissions as indicated below:

- a. **Exemption:** Protocols that are of minimal risk and meet one of the criteria for exemption as outlined in Chapter 12, may be exempted from some specific HRPP requirements. The exemption is from the requirement to hold a valid assurance, review by a full IRB and protocol approval from an IO. The protocol may also be exempted from the requirement for maintaining signed documentation of informed consent.

-
- b. **Minimal Risk–Expedited Review:** Protocols that are of minimal risk and meet one of the categories for expedited review as outlined in Chapter 13, but do not have to receive expedited review.
 - c. **Minimal Risk–Convened IRB Review:** Protocols that are of minimal risk but do not clearly meet the requirements listed in 9.3.a or 9.3.b will be sent to the convened IRB for review. If the Chair and Vice-Chair are not in agreement based on their preliminary review, and do not reach a consensus, the protocol shall be submitted to the convened IRB for review.
 - d. **Greater Than Minimal Risk:** Protocols that are determined to be greater than minimal risk by the Chair and Vice-Chair, must be submitted to the convened IRB for review.

All reviews completed by the Chair or Vice-Chair are presented to the convened IRB at the next scheduled meeting. These and all other determinations are subject to subsequent review and endorsement by the convened IRB.

9.4 Convened IRB Review

When all preliminary requirements have been met, the convened IRB meets to receive reports on applicability and preliminary reviews and to consider the other research protocol packages, promptly notifying PIs if changes are required to the protocols prior to approval. During the meeting the convened IRB will:

- a. Review each research protocol, confirming the assigned level of risk.
- b. Determine if (a) 32 CFR 219.111, (b) DoD-DON requirements, and (c) other state, federal, or international requirements are met
- c. Ask a PI to discuss the procedures to be performed or to answer questions if additional information is needed to achieve sufficient understanding of the research.
- d. For all projects or tasks, make an approval recommendation using the guidelines in Chapter 14. In this case the IRB may:
 - 1. Recommend approval as submitted.
 - 2. Require modifications in order to secure approval. In this case the IRB may approve pending review or verification of minor IRB required modifications by the IRB Chair and Vice Chair or convened IRB. Protocols found by the IRB to require significant modifications must be brought back before the convened IRB for review or verification. Required review will be documented in the convened IRB minutes.
 - 3. Recommend disapproval. The IRB shall clearly describe the reasons for recommending disapproval. The IO is prohibited from approving a protocol when the IRB has recommended disapproval.

-
4. Recommend deferral of the review to a DoD IRB in place at an institution or organization where the research is to be executed.
 5. Recommend that certain projects require more than annual review.
 6. Recommend that certain projects have third parties observe research or consent processes.
- e. For greater than minimal risk research (or minimal risk research in which the IRB deems it necessary):
1. Identify and approve a named research monitor, or approve a research monitor identified by the PI. Approve a written summary of the monitor's duties, authorities and responsibilities. In addition to completing the same training required of the PI and associate investigators, it is desired that the research monitor have experience with human subject research and the particular type of research being monitored.
 2. Identify and approve a named ombudsman, or approve an ombudsman identified by the PI, for research involving military members, or federal employees of the DoD, when recruitment occurs in a group setting. The ombudsman shall not be associated in any way to the research and shall be present during the recruitment in order to monitor that the voluntary involvement or recruitment of the military members or DoD employees is clearly and adequately stressed and that the information provided about the research is clear, adequate and accurate.

9.5 IO Package Review

When the research protocols have been reviewed and recommendations have been voted upon by the convened IRB, or the Chair and Vice-Chair in the case of expedited reviews, a review package is assembled and forwarded to the IO. The IRB Chair shall notify the PIs of the recommendations forwarded to the IO and shall provide the PI with a copy of the IO's action on their research protocol.

The packages include:

- a. The minutes of the IRB meeting (if applicable).
- b. The IRB assessment of the risk level, which must be either minimal risk or greater than minimal risk.
- c. The IRB recommendations regarding approvals.
- d. The assignment and responsibilities of the research monitor(s) for a protocol involving greater than minimal risk.
- e. The assignment and responsibilities of the ombudsman when required.
- f. The anonymous dissenting opinion(s) of board member(s), if any.

-
- g. The final research protocol, informed consent form, and all supporting documentation.
 - h. Copies of or documentation of approved IIAs, IAIRs and other research agreements (if applicable).

9.6 IO Approval Authority

Upon review of protocol packages, the IO may take one of the following actions:

- a. Approve the IRB recommendations,
- b. Require additional safeguards or modifications,
- c. Forward the review package to a higher reviewing authority, or
- d. Disapprove the protocol.

Under no circumstances may the IO approve a protocol that the IRB has recommended for disapproval. The IO may request that the IRB reconsider its disapproval recommendation.

When a protocol receives final approval, the IO issues an Approval Letter to the PI for a period determined by the IRB, not to exceed one year from date of IRB review. Only thereafter may recruitment and research begin.

9.7 DON HRPP Review

The IRB Chair forwards all protocols and supporting documentation signed by the IO to DON HRPP for Department of the Navy Headquarters (HQ) level review. For protocols reviewed by the Marine Corps IRB on behalf of an Institution supported through an IAIR or other research agreement, the IRB Chair will forward a copy of the IO's approval and all protocol documentation to the Institution's appointed Human Research Protection Point of Contact.




Figure 9-1. IRB Review Process

Chapter 10: IRB Protocol Submission Package for Human Subjects Research

The research protocol for human subjects research, whether needing convened IRB review, expedited review, or exemption determination shall be submitted to the IRB Administrator, and, at a minimum, shall include all the elements found in Appendix D.

The protocol shall be submitted with:

- a. An IRB Action Request, Appendix C.
- b. A copy of the informed consent document, if required.
- c. A signed Investigator Affirmation for all investigators (PI and associate investigators), Appendix E.
- d. Training documentation for PI and training plan for all investigators to include CITI training and project specific training.
- e. Evidence of an independent scientific review.
- f. Supervisor signature.
- g. Local Marine Corps command support/non-support of protocol.
- h. Individual Investigator Agreement (IIA) for any member of the research team not covered under the Marine Corps assurance.
- i. Institutional Agreement for IRB Review (IAIR) when collaborating with an institution or investigator that is covered by a separate DoD or Federal Assurance.

For protocols determined to be greater than minimal risk, additional requirements are found in Chapter 11.

Chapter 11: Greater Than Minimal Risk

Due to the increased possibility of injury (whether physical, psychological, financial, social, or other) arising from participation in human subject research, every protocol involving greater than minimal risk shall include an arrangement for emergency treatment and necessary follow-up of any research-related injury. The IRB will determine whether research involving minimal risk also might include a similar arrangement for research-related injury.

1. An appropriate emergency treatment plan shall be developed and necessary personnel training completed, before exposure of the subject to the research risk. Sufficient supplies and equipment shall be available to administer immediate care and stabilize the subject for transport to an appropriate medical facility if appropriate or triage other harms as might occur. Arrangements shall be made in advance for timely emergency transport from the site of the research to a competent medical facility in the event of need.
2. A research monitor(s) must be assigned to the project. In addition to the basic qualifications listed in Paragraph 3, it is desired that the research monitor have experience with human subjects research and the particular type of research being monitored.
3. If the research is bio/medical in nature, the research monitor or at least one member of the research team or biomedical support staff shall be in close proximity to the research subject at all times during research related activities. This person shall have at least current basic life support (BLS) training, familiarity with any special equipment or clothing worn by the subject, and have a means to immediately summon assistance.
4. In all research involving significant physiological stress to the research subject, specific parameters shall be included in the research protocol clearly specifying the criteria both for cessation of the subject's exposure to the stress and for their elimination or disqualification from the project.
5. For research involving greater than minimal risk and also involving military personnel, unit officers and noncommissioned officers (NCOs) shall not influence the decisions of their subordinates to participate or not to participate as research subjects as required in reference (d). Unit officers and senior NCOs in the chain of command shall not be present at the time of research subject solicitation and consent during any research recruitment sessions in which members of units under their command are afforded the opportunity to participate as research subjects. When applicable, officers and NCOs so excluded shall be afforded the opportunity to participate as research subjects in a separate recruitment session. During recruitment briefings to a unit where a percentage of the unit is being recruited to participate as a group, an ombudsman not connected in any way with the proposed research or the unit shall be present to monitor that the voluntary nature of individual participants is adequately stressed and that the information provided about the research is adequate and accurate.

Chapter 12: Research That Meets Criteria For Exemption

All human subjects research activities under Marine Corps jurisdiction shall be reviewed to determine whether the research meets one or more of the exemption categories described in reference (b). The IRB may not create new categories of exempt research. Only the IRB Chair or a Vice-Chair may determine which activities meet one of the categories as exempt research. See Appendix A for a listing of the categories of exemption.

Research that meets criteria for exemption is subject to the same ethical standards, human subject protections, and applicable DoD, DON, and Marine Corps policies and procedures as research that is determined not to meet the criteria for exemption; however, there is no inherent requirement to provide documentation of informed consent or continuing review, but the IRB may require these if deemed appropriate.

Final determination whether or not a research activity meets criteria for exemption from further IRB review will be provided to the PI in writing. The documentation will include the citation of the specific category justifying the exemption [i.e., Ref (b)-32 CFR 219.101(b) (1-6)]. Research that meets criteria for exemption shall be forwarded to DON HRPP for headquarters level review.

Any proposed changes to a protocol determined to meet criteria for exemption must be submitted to the IRB prior to implementation. The proposed change(s) must be submitted as part of the previously exempt protocol. Certain changes may disqualify the research from meeting an exemption and require either an expedited convened IRB review.

The IO approves all human subjects research under their jurisdiction even if the research qualifies for exemption under reference (b). Because a protocol meets criteria for exemption under the rule does not mean the IRB is under any obligation to determine that the study is exempt from the regulations. The IRB may impose a higher level of protection for subjects but may not approve a lower level of protection than that indicated by exemption or expedited research processes.

Chapter 13: Expedited Review Process

The IRB Chair and Vice-Chair shall determine whether research protocols meet criteria for review under expedited procedures as defined in references (b) and (h).

13.1 Expedited Review Categories

The expedited review process is intended to streamline the review process without any decrease in the level of protection of the human subject.

- a. The activities listed should not be deemed to be of minimal risk simply because they are included on this list. Inclusion on this list merely means that the activity is eligible for review through the expedited review procedure when the specific circumstances of the proposed research involve no more than minimal risk to human subjects.
- b. The research categories, as found in reference (h) are listed in Appendix B. Categories 1 through 7 pertain to both initial and continuing IRB review.

13.2 Expedited Review Criteria

1. The IRB Chair and Vice-Chair may initiate an expedited review procedure for two specific cases:
 - a. Review of research activities that involve no more than minimal risk and that fall into one or more of the nine categories as listed in Appendix B.
 - b. Minor changes to research protocols approved within the last year.
2. All other research, unless determined to meet a category as exempt research, regardless of the assigned level of risk, must be reviewed by the convened IRB.
3. Under the expedited review process, the reviewers may exercise all of the authorities of the IRB, including requiring changes for approval, but the reviewer may not recommend disapproval, which is reserved for the convened IRB.
4. If changes requested under an expedited review are unacceptable to the researcher, he or she may request review by the convened IRB under regular review procedures.
5. The IO reviews all expedited review protocols and has the same approval and disapproval options as listed in section 9.6 (IO Approval Authority).
6. The IO may restrict, temporarily suspend, or choose not to authorize use of the expedited review procedure.
7. The expedited review process may not be used for the following:
 - a. Any classified research projects involving human subjects

-
- b. Any greater than minimal risk research.
 - c. Where identification of the subjects and/or their responses would reasonably place them at risk of criminal or civil liability or be damaging to the subjects' financial standing, employability, insurability, reputation, or be stigmatizing, unless reasonable and appropriate protections will be implemented so that risks related to invasion of privacy and breach of confidentiality are no greater than minimal.
 - d. Any research involving pregnant women, children, or prisoners.

Chapter 14: Criteria for Approval of Research

In order to approve research covered by this policy the IRB shall determine that all of the following requirements are satisfied:

1. Risks to subjects are minimized:
 - a. By using procedures which are consistent with sound research design and which do not unnecessarily expose subjects to risk, and
 - b. Whenever appropriate, by using procedures already being performed on the subjects for diagnostic or treatment purposes.
2. Risks to subjects are reasonable in relation to anticipated benefits, if any, to subjects, and the importance of the knowledge that may reasonably be expected to result. In evaluating risks and benefits, the IRB should consider only those risks and benefits that may result from the research (as distinguished from risks and benefits of therapies subjects would receive even if not participating in the research). The IRB should not consider possible long-range effects of applying knowledge gained in the research (for example, the possible effects of the research on public policy) as among those research risks that fall within the purview of its responsibility.
3. Selection of subjects is equitable. In making this assessment the IRB should take into account the purposes of the research and the setting in which the research will be conducted and should be particularly cognizant of the special problems of research involving vulnerable populations, such as children, prisoners, pregnant women, military personnel, mentally disabled persons, or economically or educationally disadvantaged persons.
4. Informed consent will be sought from each prospective subject or the subject's legally authorized representative, in accordance with, and to the extent required by reference (b).
5. Informed consent will be appropriately documented, in accordance with, and to the extent required by reference (b).
6. When appropriate, the research plan makes adequate provision for monitoring the data collected to ensure the safety of subjects.
7. When appropriate, there are adequate provisions to protect the privacy of subjects and to maintain the confidentiality of data.
 - a. When some or all of the subjects are likely to be vulnerable to coercion or undue influence, such as children, military personnel, DoD civilians, prisoners, pregnant women, mentally disabled persons, or economically or educationally disadvantaged persons, additional safeguards have been included in the study to protect the rights and welfare of these subjects.

Chapter 15: Informed Consent

Voluntary informed consent is fundamental to ethical research involving human subjects. Informed consent is not simply a document; it is a process of ensuring that persons who agree to take part in research are fully informed about the potential risks and benefits from their participation. No investigator may involve a human subject in research covered by this instruction unless the subject is a volunteer and the investigator has obtained informed consent from the subject. The Marine Corps limits human subjects research under its purview to adults that can give their own informed consent.

There may be some elements of confidentiality or anonymity that are in conflict with a military subject's responsibility to report knowledge of criminal conduct or violations of the Uniformed Code of Military Conduct. Where this conflict exists, informed consent documents will contain specific language pertaining to the limits of confidentiality.

The elements of informed consent are presented herein. Depending on the research, ongoing discussion with, and education of, subjects may continue long after the original informed consent is obtained. For additional requirements on informed consent refer to reference (b) and (c).

15.1 General Informed Consent Requirements

1. Informed consent must be obtained from each prospective subject and include all the elements of informed consent found in Section 15.2 (Required Elements of Informed Consent).
2. Information must be given in a language and manner understandable to the subject.
3. The IRB may require that additional information be given to the subject when the information would meaningfully add to the protection of the rights or welfare of the subject.
4. Informed consent will be appropriately documented, including date, subject, researcher signatures, and witness signatures as required by the IRB.
5. The IRB may waive the requirement for informed consent documentation as outlined in reference (b) only if:
 - a. The research presents no more than minimal risk and involves no procedures for which written consent is normally required outside of the research context, or
 - b. The only record linking the subject and the research would be the consent document and the principal risk would be potential harm resulting from breach of confidentiality.

In cases in which the documentation is waived, the IRB will require that informed consent be obtained orally, and a script of such informed consent must be submitted to the IRB. The IRB may require the investigator to provide subjects with a written

statement regarding the research and document the informed consent in research records, field notes, etc. For surveys that are administered via the internet, informed consent documentation may be met by having the subject select an appropriate block on the informed consent page of the survey. The subject would be blocked from proceeding with the survey in the absence of the "acknowledgement" block being indicated. The IRB will also determine applicability and implementation of 10 USC 980.

6. An investigator shall seek informed consent only under circumstances that provide the prospective subject sufficient opportunity to consider whether to participate in the study, and that minimize the possibility of coercion or undue influence.
7. Informed consent may not include any exculpatory language through which the subject is made to waive, or appear to waive, any of the subject's legal rights, or releases or appears to release the investigator, the sponsor, or the government or its agents from liability for negligence.
8. Nothing in this policy shall be taken to preempt any guidance that requires disclosure of additional information.
9. Unless a waiver of informed consent documentation is approved by the IRB, participants are given a copy of the signed informed consent document to keep.

15.2 Required Elements of Informed Consent

1. **All Projects.** At a minimum, the following information shall be provided in the informed consent process to every subject involved in any research covered by this instruction:
 - a. A statement that the study involves research, an explanation of the purposes of the research and the expected duration of the subject's participation, a description of the procedures to be followed, and identification of any procedures which are experimental;
 - b. A description of any reasonably foreseeable risks or discomforts to the subject;
 - c. A description of any benefits to the subject or to others which may reasonably be expected from the research;
 - d. A disclosure of appropriate alternative procedures or courses of treatment, if any, that might be advantageous to the subject;
 - e. A statement describing the extent, if any, to which confidentiality of records identifying the subject will be maintained;
 - f. For research involving greater than minimal risk, an explanation as to whether any compensation and an explanation as to whether any medical treatments are available if injury occurs and, if so, what they consist of, or where further information may be obtained;

-
- g. An explanation of whom to contact for answers to pertinent questions about the research and research subjects' rights, and whom to contact in the event of a research-related injury to the subject; and
 - h. A statement that participation is voluntary, refusal to participate will involve no penalty or loss of benefits to which the subject is otherwise entitled, and the subject may discontinue participation at any time without penalty or loss of benefits to which the subject is otherwise entitled.

2. **Additional Elements.** When appropriate, one or more of the following elements of information shall be provided to each subject.

- a. A statement that the particular treatment or procedure may involve risks to the subject (or to the embryo or fetus, if the subject is or may become pregnant) which are currently unforeseeable;
- b. Anticipated circumstances under which the subject's participation may be terminated by the investigator without regard to the subject's consent;
- c. Any additional costs to the subject that may result from participation in the research;
- d. The consequences of a subject's decision to withdraw from the research and procedures for orderly termination of participation by the subject;
- e. A statement that significant new findings developed during the course of the research which may relate to the subject's willingness to continue participation will be provided to the subject; and
- f. The approximate number of subjects involved in the study.

3. **Greater Than Minimal Risk.** When exposure to greater than minimal risk is involved, the following additional elements of information shall be provided to each subject in the informed consent:

- a. An explanation as to whether any compensation is available and an explanation as to whether any medical treatment is available, if injury were to occur, and, if so, of what they consist, or where further information may be obtained.
- b. The name, position, phone number, and mailing address of the designated research monitor. This allows the subject to obtain answers to pertinent questions about possible research-related medical injury or conditions that might arise during or after the study.

Chapter 16: Review and Reporting Requirements

An IRB shall conduct a Continuing Review (CR) of research covered by this policy at intervals appropriate to the degree of risk, but not less than once per year. Unless otherwise documented, the Marine Corps requires continuing review annually. Protocols that were judged to be not human subjects research or meet exemption criteria are not subject to CR unless directed by the IRB. Administrative extension of the approval period is prohibited. The IRB shall direct expired research be discontinued. A CR must be properly completed and re-approval granted prior to the end of the approval period to avoid interruption of the research. The CR shall be conducted in a manner similar to the initial review, with review of documents and a formal meeting. An expedited CR procedure may be used for all research protocols originally approved using an expedited review process or for protocols that qualify for expedited review under category 8 or 9 of Appendix B. Unlike the original protocol reviews, which assess potential impact of the protocol as planned, CRs involve a complete re-evaluation of the risk-benefit ratio based on actual experience with the conduct of the research and the actual impact on human subjects to date.

1. The PI shall submit a CR package to include an IRB Action Request (Appendix C) and a CR Report (Appendix F) to the IRB Administrator.
2. The IRB shall:
 - a. Review the CR report and any other documentation submitted by the PI.
 - b. Determine that the risk-benefit ratio has not changed unfavorably and that the actual risks are as originally anticipated.
 - c. Determine if the informed consent process has been both adequate and properly documented using only the IRB approved consent documents. Make recommendations to correct any deficiencies.
 - d. Verify that subjects enrolled fit selection and exclusion criteria.
 - e. Consider whether there has been adequate protection of the subjects' privacy and confidentiality of data, including storage and handling of previously collected personally identifiable data.
 - f. Specifically approve a new updated informed consent document, unless the IRB did not originally require informed consent documentation.
 - g. Document its discussions, recommendations, and votes on each CR separately in the minutes.
 - h. As part of the CR, the IRB (or Chair/Vice-Chair if expedited review is used) may reclassify the risk of a protocol if, in their judgment, the new classification better captures the actual risk to subjects.

-
- i. Ensure prompt reporting of proposed changes in research and for ensuring changes may not be initiated without IRB review and approval except when necessary to eliminate apparent immediate hazards to the subject
 3. The IRB shall consider all information in an overall perspective when making their recommendations for continuation.
 4. The IRB may recommend one of the following actions:
 - a. Approve continuation of the research without change.
 - b. Add requirements for continued approval.
 - c. Suspend (temporarily) or terminate (permanently) the research effort.
 - d. Verify from sources other than the investigators that no material changes have occurred since previous IRB review
 5. The review package shall be forwarded to the IO for action. The IO must take actions analogous to those prescribed for initial project review.
 6. All reports and documentation related to the CR must be submitted to DON HRPP for HQ level review.

Chapter 17: Scientific Review

Per references, an independent review of research for scientific merit or scholarship is required prior to IRB review. Appropriate individual(s), committees and/or groups other than the IRB must complete a scientific review for ensuring scientific soundness. Since each scientific discipline contains distinct theories and methods, there can be no one absolute standard against which all studies can be assessed. Determining the scientific soundness of a study requires expert judgment about the degree to which the theoretical and methodological approach in a research design is appropriate to the topic and specific questions being investigated.

PI's may choose from a wide variety of resources for such a review. Acceptable sources of scientific review may include, but are not limited to, peer review or local scientific review boards. "Peers" can include, but are not limited to, group leads or project leads knowledgeable about the proposed research approach, with no conflict of interest. Qualifications of the reviewing peer or body must be included on the review summary. Qualifications include at least reviewer titles, location, area of expertise, relationship to PI, and a statement supporting their appropriateness as a reviewer.

The following is a description of the approach for conducting the scientific review, the minimum criteria to be used, and the approach for conveying the review.

1. The scientific review should consist of a review of the protocol, augmented by interactions with the principal investigator, as needed, for clarification.
2. The reviewer should consider the following questions when going through the protocol:
 - a. Purpose(s): Is/are the objectives clearly stated?
 - b. Approach:
 - i. Does the approach follow a sound, scientific process (with recognition that processes may differ based on the type of research being conducted)?
 - ii. Are the conceptual framework, design, methods and planned analysis adequately developed, well integrated, and appropriate to the aims of the project and the nature of the data collection site(s)?
 - iii. If applicable, are the kinds of results this design can produce appropriately matched with the scientific or programmatic claims the researchers hope to make?
 - iv. Are the limitations of different aspects of the design clearly articulated?
 - v. Does the investigator acknowledge potential problem areas and consider alternative research approaches?

-
- c. Investigator:
- i. Are the Principal Investigator (PI) and Associate Investigators (the research team) appropriately qualified to carry out this work and/or is there an appropriate plan to train associate investigators?
 - ii. If applicable, is the PI appropriately trained and well suited to supervise other investigators?
3. The scientific reviewer will provide an assessment to the PI, who will include a copy of the review when submitting the protocol to the IRB Chair and the Administrator, by e-mail that provides explicit responses to the questions above. The reviewer should include a recommendation either that the IRB initiate its review or provide feedback to the PI regarding changes to the protocol to satisfy the scientific review.

Chapter 18: Non-compliance, Misconduct, Adverse Events, Unanticipated Problems

18.1 Allegations of Non-compliance with Human Subject Protections

All participants, including human subjects, researchers, or support personnel shall be informed of their right to report concerns of non-compliance to the PI, IRB Chair, or IRB Vice-Chair immediately. The Marine Corps IRB and an Institutional Official will review all allegations of non-compliance with human subject protections and take action, if appropriate. The IRB Chair must report the initiation of all investigations and report results regardless of the findings to DON HRPP and appropriate research sponsors.

18.2 Allegations of Research Misconduct

All participants, including human subjects, researchers, or support personnel shall be informed of their right to report concerns of misconduct to the PI, IRB Chair, or IRB Vice-Chair immediately. The Institutional Official will review all allegations of research misconduct and take action if appropriate. The IRB Chair must report the initiation of all investigations and report results regardless of the findings to DON HRPP and appropriate sponsors as outlined in reference (n).

18.3 Unanticipated Problems Involving Risk to Subjects or Others (UPIRTSO)

UPIRTSOs are any incident, experience, or outcome that meets ALL three of the following conditions:

1. Is unexpected (in terms of nature, severity or frequency) given the procedures described in the research protocol documents (e.g., the IRB-approved research protocol and informed consent document) and the characteristics of the human subject populations being studied.
2. Is related or possibly related to participation in the research (in this policy possibly related means there is a reasonable possibility that the incident, experience, or outcome may have been caused by the procedures involved in the research).
3. Suggests that the research places human subjects or others at a greater risk of harm (including physical, psychological, economic, or social harm) than was previously known or recognized, even if no harm has actually occurred.

UPIRTSOs must be reported to the IRB Chair/Vice Chair immediately, reviewed by the convened IRB and forwarded to the IO for submission to DON HRPP.

18.4 Serious Adverse Events

Serious adverse events are those with serious effect or potential for serious effect, whether or not the event was expected to occur during the research. Obvious serious events include death, hospitalization, disability, severe emotional distress, or significant injury or illness. They also include deviations from research protocol, which increase potential risk to subjects. Anticipated deviations from research protocol must be pre-approved by the IRB through the protocol modification process. PIs must ensure that investigators (or any research personnel who interact with subjects) take action immediately to avoid further adverse events or harm to the subject. If appropriate, research should be suspended until problems can be identified and resolved. The PI shall verbally notify the IRB Chair immediately and submit an Adverse Event Report (Appendix H) with an IRB Action Request (Appendix C) to the IRB Chair within 24 hours of the event. The report shall include the PI's (and that of the research monitor, if used) evaluation of the experience and recommend corrective action. If the IRB Chair does not concur with the recommendations, additional safeguards may be required. The Chair shall also provide a copy to the IRB, who may in turn choose to impose additional safeguards. The adverse event report and IRB recommendation will be forwarded to the IO within seven working days. The IO may impose additional safeguards but may not remove or reduce any safeguards imposed by the IRB. The IRB Chair shall report final decisions, endorse the PI's report, and forward the documentation to DON HRPP within 15 working days of the discovery of the serious adverse event.

18.5 Unanticipated Problems

Adverse events that are not considered serious but which may impact the research or the resolution of which might alter the research protocol are considered unanticipated problems. Unanticipated problems include those where a subject experiences embarrassment, financial hardship, adverse administrative action, or career impact. Other examples include enrollment of subjects that do not meet the criteria and where there is reasonable risk of harm, or failure to have informed consent documentation if required by the protocol, protocol deviations, and subject complaints. The PI shall submit an Adverse Event Report (Appendix H) with an IRB Action Request (Appendix C) to the IRB Chair via the IRB Administrator within 15 days of the event. The Chair shall review the report and decide on what corrective actions, if any should be made to the research protocol. If appropriate, research may be suspended until problems can be identified and resolved.

18.6 Summary Reporting

Summaries of all allegations of non-compliance and misconduct, UPIRTSOs, serious adverse events, and unanticipated problems must be submitted to the IRB along with each subsequent CR Report and Project completion Report.

Chapter 19: IRB Review Requirements for External DoD Institutions

The Marine Corps IRB may review protocols in which the Marine Corps has no involvement. The Marine Corps' IRB will only review protocols from other DoD institutions that have obtained the appropriate DoD Assurance. A DoD institution does not need to list the Marine Corps IRB as a reviewing IRB on its Assurance for a one-time review. An Institutional Agreement for IRB Review (IAIR) is used in this case. The only time a DoD institution will need to list the Marine Corps IRB on its Assurance is if the Marine Corps IRB will be the permanent reviewer for all of their work. The Marine Corps and the performing institution must have a signed IAIR, as provided and endorsed by DON HRPP. MCCDC IRB will review external performance site protocols only when processed in accordance with Figure 19-1.




Figure 19-1. IRB Review Process for External DoD Institutions

Chapter 20: Extramural Human Subject Research

Extramural human subjects research is research being conducted by a non-DoD and non-federal institution or organization outside of the Marine Corps, that is requesting the support of the Marine Corps either through the solicitation of Marines or federal employees of the Marine Corps as voluntary research subjects or through the use of Marine Corps facilities, resources or equipment. This institution or organization is also called an extramural performer. DON supports research with human subjects conducted at non-DoD and non-federal institutions. Any research grants, contracts, Cooperative Agreements, Cooperative Research and Development Agreements (CRADAs), Work for Private Party Agreements, Educational Partnership Agreements, involvement in Small Business Innovative Research (SBIR) or other transactions, hereafter collectively considered "binding agreements," must include the additional DoD and DON requirements for human subject protections. The institution performing the research also must meet all the requirements of this policy and procedures manual as well as those in references (e) and (r).

Extramural performers that plan to recruit Marine Corps personnel as voluntary subjects, regardless of if the project is funded by DoD/DON, must submit documentation for a Marine Corps' administrative review (referred to as a DON Review). A DON Review is not an IRB review but rather a second level administrative review to ensure the extramural performer has taken into consideration DoD requirements for conducting human subject research. Documentation should be submitted to the Marine Corps IRB Chair (or designated Vice Chair) for review via the IRB administrator. Documentation should include:

1. Extramural Performer's Federalwide Assurance (FWA) Number and Expiration Date
2. Extramural Performer's DoD Addendum to FWA and Expiration Date
3. A Copy of the Complete Protocol, to include the recruitment plan
4. A Copy of the IRB approved Informed Consent Form(s)
5. General Officer level approval from the Headquarters Marine Corps department with program oversight, based on the topic of the research (seek IRB Chair advise if unsure whether this approval is required)
6. Local Commander's approval to solicit participants or utilize facilities. Approval must be at the O-5 or O-6 Level.
7. Extramural Performer's IRB Review results (to include category of exemption or expedited review if appropriate)
8. Research Staff's Human Subjects Research Protection Ethics Training. Specific training has been designed for non-DoD researchers to ensure familiarity with additional protections provided military members as a vulnerable population under reference (d).

Chapter 21: Collaborative Research

This policy and procedure manual allows for the collaboration of institutions to avoid duplication of effort in research and IRB review. One of the participating activities shall be designated in writing within the binding agreement as having the primary responsibility for the protection of the human subjects. The activity with the primary responsibility must exercise that responsibility even during phases of the research carried out by another activity. Such reliance on other IRBs must not compromise any federal standards or Navy requirements. All collaborators must ensure compliance with all relevant human subject protection regulations at their sites. Binding agreements among institutions or organizations require written confirmation of an Institutional Assurance with DoD-Navy Addendum, plus a Statement of Work (SOW) and specific assignment of responsibilities and IRB oversight.

As stated in Chapter 5.1.14, and Chapter 10, PI's, internal and external to the Marine Corps must obtain written support/non-support of a protocol from the local Marine Corps Commander(s) where the protocol is intended to be conducted. Local command support/non-support of a protocol doesn't constitute Marine Corps institutional approval/disapproval of the protocol.

If the human subjects research is to be conducted under grant or contract by an organization or institution with an approved IRB, the PI forwards a copy of the package submitted to that IRB along with a cover memorandum indicating the status of the protocol to the Marine Corps IRB for file. When human subjects research is conducted under binding agreements, the IRB submission package must include the agreement title page, cover page and the SOW.

Changes to a human subjects research protocol may not be made without the prior approval of the responsible IRB.

21.1 Collaborative Research with another DoD/DON Institution

Delineate institutional responsibilities when performing research involving human subjects in collaboration with another DoD/DON institution. These responsibilities should include establishing written agreements for tasks such as minimizing the number of institutional review boards (IRBs) that review and approve the research. Per reference (d), when any institution relies upon another institution's IRB, there must be a written agreement defining the responsibilities and authorities of each organization in complying with the terms of each institution's Federal assurance (e.g., an Institutional Agreement for IRB Review).

21.2 Collaborative Research with a Non-DoD Institution

The Marine Corps may rely on a collaborating non-DoD institution's IRB if the minimum conditions outlined in reference (d), paragraph (3)(8) are met.

21.3 Collaborative Effort with an Associate Investigator Not Affiliated with the Marine Corps:

An appropriate written agreement endorsed by the DON HRPP shall be established to bring an individual investigator who is associated with the Marine Corps and conducting research, but not employed by the Marine Corps, under the appropriate DON Assurance. Under this requirement, a fully executed agreement would place an individual investigator under the authority of the Marine Corps' human subject policies and procedures and allow a Marine Corps PI to include the individual investigator on a research project that includes human subjects research. This agreement normally is not intended to be used if an individual is employed by an institution that has its own Assurance; in that case, the individual would be included on a Marine Corps research project through a collaboration agreement as described above.

References

- (a) Title 10, United States Code, Section 980, Limitation on Use of Humans as Experimental Subjects
- (b) Title 32, Code of Federal Regulations Part 219, Protection of Human Subjects
- (c) Title 45, Code of Federal Regulations Part 46, subparts B, C, and D, Protection of Human Subjects
- (d) DoD Instruction 3216.02, Protection of Human Subjects and Adherence to Ethical Standards in DoD-Supported Research
- (e) SECNAVINST 3900.39 (Series), Human Research Protection Program
- (f) The Belmont Report, 44 Federal Register 23192 of 18 April 1979
- (g) SECDEF Memo, 13 December 1999, Interim Policy for Protection of Human Subjects in Classified Research
- (h) Title 63, Federal Register 60364-60367 of 9 Nov 98, DHHS, Determination of Review by IRB Through Expedited Review Procedure
- (i) DoD Directive 5230.9, Clearance of DoD Information for Public Release
- (j) SECNAVINST 5720.44B, Public Affairs Policy
- (k) DoD Directive 2310.01E, DoD Enemy Prisoner of War Detainees Program
- (l) OPNAVINST 5300.8C, Coordination and Control of Personnel Surveys
- (m) SECNAV M-52 10.1, Records Management Manual
- (n) DoD Instruction 3210.7, Research Integrity and Misconduct
- (o) Title 21, Code of Federal Regulations Food and Drugs Chapter I - Food and Drugs Administration, Department of Health and Human Services, Sub Chapter A, Part 56, Institutional Review Boards
- (p) Title 21, Code of Federal Regulations, Food and Drugs Chapter I - Food and Drugs Administration, Department of Health and Human Services, Sub Chapter A, Part 50 Protection of Human Subjects
- (q) Title 5, U. S. Code Section 3109, Employment of Experts and Consultants; Temporary and Interim.
- (r) DFARS 252.235-7004, Protection of Human Subjects

-
- (s) Minimum Education Requirements for DoD Personnel Involved in Human Research Protection, dated 16 Aug 2012
 - (t) Section 30 of Title 24, U.S.C.
 - (u) MCO 3900.18, Human Research Protections Program

Appendix A: Categories of Exemption

Excerpted from 32 CFR 219, Protection of Human Subjects, Section 101 (b):

"Unless otherwise required by department or agency heads, research activities in which the only involvement of human subjects will be in one or more of the following categories are exempt from this policy:

- (1) Research conducted in established or commonly accepted educational settings, involving normal educational practices, such as,
 - (i) research on regular and special education instructional strategies, or
 - (ii) research on the effectiveness of or the comparison among instructional techniques, curricula, or classroom management methods.
- (2) Research involving the use of educational tests (cognitive, diagnostic, aptitude, achievement), survey procedures, interview procedures, or observation of public behavior, unless:
 - (i) Information obtained is recorded in such a manner that human subjects can be identified, directly or through identifiers linked to the subjects; and
 - (ii) Any disclosure of the human subjects' responses outside the research could reasonably place the subjects at risk of criminal or civil liability or be damaging to the subjects' financial standing, employability, or reputation.
- (3) Research involving the use of educational tests (cognitive, diagnostic, aptitude, achievement), survey procedures, interview procedures, or observation of public behavior that is not exempt under paragraph (b)(2) of this section, if:
 - (i) The human subjects are elected or appointed public officials or candidates for public office; or
 - (ii) Federal statute(s) require(s) without exception that the confidentiality of the personally identifiable information will be maintained throughout the research and thereafter.
- (4) Research involving the collection or study of existing data, documents, records, pathological specimens, or diagnostic specimens, if these sources are publicly available or if the information is recorded by the investigator in such a manner that subjects cannot be identified directly or through identifiers linked to the subjects.
- (5) Research and demonstration projects which are conducted by or subject to the approval of department or agency heads, and which are designed to study, evaluate, or otherwise examine:
 - (i) Public benefit or service programs;

-
- (ii) Procedures for obtaining benefits or services under those programs;
 - (iii) Possible changes in or alternatives to those programs or procedures; or
 - (iv) Possible changes in methods or levels of payment for benefits or services under those programs.
- (6) Taste and food quality evaluation and consumer acceptance studies,
- (i) If wholesome foods without additives are consumed or
 - (ii) If a food is consumed that contains a food ingredient at or below the level and for a use found to be safe, or agricultural chemical or environmental contaminant at or below the level found to be safe, by the Food and Drug Administration or approved by the Environmental Protection Agency or the Food Safety and Inspection Service of the U.S. Department of Agriculture.”

Appendix B: Expedited Review Categories

1. **Expedited Review Category 1.** Clinical studies of drugs and medical devices when either condition (a) or (b) is met.

- a. Research on drugs for which an investigational new drug application is not required. (Note: Research on marketed drugs in which the research exposure would significantly increase the risks or decrease the acceptability of the risks associated with the use of the product is not eligible for expedited review.)
- b. Research on medical devices for which either
 1. an investigational new device exemption application is not required or
 2. the medical device is cleared/approved for marketing and the medical device is being used in accordance with its cleared/ approved labeling.

2. **Expedited Review Category 2.** Collection of blood samples by finger stick, heel stick, ear stick, or venipuncture according to the restrictions in the applicable category:

- a. *Healthy non-pregnant adults who weigh at least 110 pounds.* For these subjects, the amounts drawn may not exceed 550 ml in an 8-week period, and the collection may not occur more frequently than two times per week.
- b. *Other adults.* Considering the age, weight, and health of the subjects, the collection procedure, the amount of blood collected, the frequency with which it will be collected, the amount drawn may not exceed the lesser of 50 ml or 3 ml/kg in an 8-week period, and collection may not occur more frequently than two times per week.

3. **Expedited Review Category 3.** Prospective collection of biological specimens for research purposes by noninvasive means. Examples include hair and nail clippings collected in a non disfiguring manner; deciduous teeth at time of exfoliation or if routine patient care indicates a need for extraction; permanent teeth if routine care indicates a need for extraction; excreta and external secretions (including sweat); uncannulated saliva collected either in an unstimulated fashion or stimulated by chewing gum base or wax or by applying a dilute citric solution to the tongue; placenta removed at delivery; amniotic fluid obtained at the time of rupture of the membrane prior to or during delivery; supra- and subgingival dental plaque and calculus, provided the collection procedure is not more invasive than routine prophylactic scaling of the teeth and the process is accomplished in accordance with accepted prophylactic techniques; mucosal and skin cells collected by buccal scraping or swab, skin swab, or mouth washings; and sputum collected after saline mist nebulization.

4. **Expedited Review Category 4.** Collection of data through non-invasive procedures (not involving general anesthesia or sedation) routinely employed in clinical practice, excluding procedures involving x-rays, microwaves, or potentially injurious directed energy such as lasers. When medical devices are employed, they must be cleared or approved for marketing. (Note: Studies intended to evaluate the safety and effectiveness of the medical device are not generally

eligible for expedited review, including studies of cleared medical devices for new indications.)
Examples of activities that may be eligible for expedited review include:

- a. Physical sensors that are applied either to the surface of the body or at a distance and do not involve input of significant amounts of energy into the subject or an invasion of the subject's privacy;
- b. Weighing and testing sensory acuity;
- c. Magnetic resonance imaging;
- d. Electrocardiography, electroencephalography, thermography, detection of naturally occurring radioactivity, electroretinography, ultrasound, diagnostic infrared imaging, Doppler blood flow, and echocardiography;
- e. Moderate exercise, muscular strength testing, body composition assessment, and flexibility testing where appropriate given the age, weight, and health of the individual.

5. **Expedited Review Category 5.** Research involving materials (data, documents, records, or specimens) that have been collected or will be collected solely for non-research purposes, such as medical treatment or diagnosis.

6. **Expedited Review Category 6.** Collection of data from voice, video, digital, or image recordings made for research purposes.

7. **Expedited Review Category 7.** Research on individual or group characteristics or behavior (including, but not limited to, research on perception, cognition, motivation, identity, language, communication, cultural beliefs or practices, and social behavior) or research employing survey, interview, oral history, focus groups, program evaluation, human factors evaluation, or quality assurance methodologies.

8. **Expedited Review Category 8.** Continuing review of greater than minimal risk research that was previously approved by the convened IRB may be conducted using expedited review procedures if it falls into any one of the following categories:

- a. Where all three of the following conditions are met:
 - (1) The research is permanently closed to the enrollment of new subjects; and
 - (2) All subjects have completed all research-related interventions; and
 - (3) The research remains active only for long-term follow-up of subjects.
- b. Where no subjects have yet been enrolled and no additional risks have been identified since IRB review; or
- c. Where all remaining research activities are limited to data analysis.

9. **Expedited Review Category 9.** Continuing review of approved minimal risk research may be conducted using expedited review procedures when the research was originally reviewed by the convened IRB only because it did not fit into categories 2 through 7, as long as:

- a. the research was not conducted under an investigational new drug application or investigational device exemption, and
- b. no additional risks have been identified since the convened IRB review.

Appendix C: IRB Action Request

IRB Control No: _____ Date: _____

Project Title: _____

PI Name: _____ Command & Code: _____

Check appropriate statement:

1. I request approval of the attached protocol. This protocol follows the policies and procedures in the Marine Corps HRPP Policy and Procedures and its references. Proposed changes in the research activity will be reported promptly to the IRB and will not be executed without prior IRB approval except when necessary to eliminate apparent immediate hazards to the subject. (Attach Full Protocol with enclosures.)
2. I request interim release of funds in the amount of (maximum 50% of total planned funding). This research project will or may collect data from human subjects, but the experimental design is not yet complete. No data from human subjects will be collected until the research protocol has been submitted, reviewed, and approved by the IRB. Funds released will only be used for those phases of the research that do not involve human subjects. I anticipate that the research protocol will be submitted on or before (date). (Attach Full Protocol with information known at this time.)
3. I request approval of changes in this research protocol as described in the attached document(s). I understand that these changes will not be executed without IRB approval. (Attach Revised Full Protocol or memorandum with requested changes *clearly annotated*, along with any documents affected by the change.)

Provide a brief summary of proposed changes and justification:

4. I am submitting a Project Completion/Termination Report as required by the Marine Corps HRPP Policy and Procedures.
5. I am submitting a Continuing Review Report as required by the Marine Corps HRPP Policy and Procedures.
6. I am submitting an Unexpected Problem/Adverse Event Report as required by the Marine Corps HRPP Policy and Procedures.
7. Other. Please explain in detail for the Board.

I certify by my signature that this protocol
is / is **not** scientifically sound.

PI Signature

Date

Supervisor Endorsement

Date

Dates of IRB Actions

IRB Action	Date
Package Received	
Convened IRB Review or Expedited IRB Review	

IRB Action	Date
PI Notification	
Approval letter signed/forwarded	
Documents to DON HRPP	

Appendix D: Full Protocol

Title of Project/Study: _____

Planned Inclusive Dates of Study: _____

1. List of primary investigator name/command/contact information.
2. List and other individuals (internal, external, and contractor) who will interact with human subjects or have access to data collected. (Ensure all have signed Investigator's Assurances.)
3. Provide background information on the origins of the project.
4. Identify sponsor and known, as well as potential, future users of the data/results.
5. Briefly describe the objectives of the project, the research plan, and methodology with particular emphasis on direct or indirect interaction with human subject or their identifiable data. Describe why human subjects (or their data) must be used in the research and if there are any alternatives.

Objectives:

- a) Primary
- b) Secondary

Research Plans:

- a) Subjects
- b) Inclusion and Exclusion Criteria
- c) Study Design

Methodology:

6. To what other reviews if any is this study subject?
7. To what other regulations is this data collection effort subject (e.g., Privacy Act) and how will it/they be implemented?
8. How will participants be recruited? (Enclose copies of any recruitment letters, messages, etc.)
9. Describe the nature and extent of risks the collection of these data pose to the participants. Assess direct impact to the subject at the time of participation (physical, emotional), and possible future impact that the disclosure of the subject's responses could have on his/her

financial standing, career, employability, insurability, reputation, etc. Describe procedures that will be implemented to minimize this risk.

10. Describe any anticipated benefits to the participants, the Navy, and/or society.
11. How will subjects be informed of their rights? Will informed consent be obtained? (Attach a copy of the Informed Consent form or consent language to be used.)
12. Describe any question/items that will be asked or data elements that will be collected or accessed from existing databases. (Attach a copy of questions, data elements, or survey/assessment instruments. If these are currently not available, provide a sample of representative items.)
13. Do any of the questions/items/data elements used in the research involve information that is private or sensitive? If yes, describe and assess the degree of potential risk or harm to the subject if disclosed.
14. What would be the impact to the research if private or sensitive information could not be collected?
15. Describe precautions that are being used to minimize risk to the subject and safeguard the data (e.g., limiting access, storage and destruction of data, password-protected network security, etc.).
16. List all attachments to this Protocol: (e.g., Informed Consent, Survey instrument, Investigator Assurance, Privacy Act Statement, Research Plan, etc.)

Appendix E: Investigator Affirmation

I, the principal investigator or co-investigator named below, acknowledge my responsibilities for performing and monitoring the research to be conducted under the protocol entitled:

I am familiar with and understand the provisions of:

- a. DHHS Regulation, "Protection of Human Subjects," (45 CFR Part 46 the "Common Rule")
- b. DoD Regulation, "Protection of Human Subjects," (32 CFR Part 219) of 19 Aug 91
- c. DoD Instruction 3216.02 "Protection of Human Subjects and Adherence to Ethical Standards in DoD-Supported Research" of 8 Nov 11
- d. SECNAVINST 3900.39 (Series), "Protection of Human Subjects,"
- e. Privacy Act (5 USC 301, 552a (1994))
- f. Marine Corps Policy and Procedures for the Human Research Protection Program

I will abide by all applicable laws and regulations, and agree that in all cases, the most restrictive regulation related to a given aspect of research involving protection of research volunteers will be followed. In the event that I have a question regarding my obligations during the conduct of this Marine Corps sponsored project, I have ready access to each of these regulations, as either my personal copy or those maintained by the Marine Corps IRB. I understand that my immediate resource for clarification of any issues related to the protection of research volunteers is the Marine Corps IRB.

	Printed Name	Signature	(MM/DD/YY)
Principal Investigator			
Associate Investigator			
Associate Investigator			
Associate Investigator			

Appendix F: Continuing Review Report

IRB Control No: _____ Date: _____

Project Title: _____

PI Name: _____ Command & Code: _____

Planned Inclusive Dates of Research: _____

Complete the following items:

1. List names of current investigative staff working on this project. (Ensure all have signed the Investigator's Assurance.)
2. Summarize progress of the research to date.
3. Describe significant events and problems particularly those that may relate to human subjects issues.
4. Describe any significant changes in, or deviations from, the protocol since it was last approved.
5. Summarize any new information (identified in the research or in a search of other literature), which may alter previous assessment of the risk-benefit to human subjects of the research.
6. Describe any remaining work on the project involving human subjects or identifiable personal data. Include scheduled completion date.
7. Explain any unplanned delays affecting the selection or use of human subjects.
8. Summarize the demographics of selected subjects to include the total number of subjects who gave consent to participate, number of male and female participants (if known), and the number of participants by racial/ethnic group (if known).
9. Were any subjects included who did not meet the selection criteria or should otherwise have been excluded? If so, please explain the circumstances.
10. Describe the number of incidents and reasons (if known) for subjects' inability or unwillingness to continue participation.
11. Summarize any complaints about the research received from subjects or those investigators who have interacted with subjects.
12. Attach a copy of the current Informed Consent/Privacy Act document/language being used in this study and any Adverse Event Reports, if applicable.

Appendix G: Project Completion Report

IRB Control No: _____ Date: _____

Project Title: _____

PI Name: _____ Command & Code: _____

Inclusive Dates of Research Performance: _____

Total Number of Subjects: _____

Complete the following items.

1. Investigate staff (list of names of all principal and associate investigators and any other personnel who worked on the project).
2. Summarize research objectives.
3. Summarize research performed focusing on human subject involvement. Describe the enrollee population appropriate to the study (e.g. by gender, pay grade/designator, enlisted/officer etc.).
4. Summarize any adverse events, problems, or complaints and how they were handled.
5. Summarize the circumstances for withdrawal or dropping of subjects who did not complete the study for whatever reason. For surveys, include response rate and any known factors adversely affecting completion.
6. Summarize any lessons learned or problems with study methodology (including informed consent process) particularly as they relate to the protection of human subjects issues.
7. State the benefits of research.
8. List briefings, professional presentation, and publication resulting (or pending) from this project. If pending items, list estimated date of completion for each.

Appendix H: UPIRTSO/Unanticipated Problem or Serious Adverse Event Report

IRB Control No: _____ Date: _____

Project Title: _____

PI Name: _____ Command & Code: _____

Type of Report: *(refer to Chapter 18 of Policy and Procedures for Marine Corps Human Research Protection Program)*

Unanticipated Problem involving Risk to Subjects or Others (UPIRTSO)

Unanticipated Problem

Serious Adverse Event

Date event occurred (if known): _____

Date event discovered: _____

1. Clearly summarize the adverse event (s). Describe any actions taken following the event(s).
2. How does this event (do these events) relate to the research (e.g., directly caused by the research, tangential to the research, an unrelated event)?
3. Discuss any patterns or trends among all adverse events occurring on this project.
4. Describe recommendations for changes in protocol to correct for and prevent future adverse events.

Appendix I: Documentation Checklist for Investigators, IRB, and DON HRPP

Excerpted from the DON HRPP Document List found on DON HRPP website.

	PU File	IRB File	Send DON HRPP
Initial Review of New Protocol			
Document granting approval to start research (approval letter)	X	X	X
Education and training documentation	X	X	N/A
Scientific review and approval document (IRB Action Request signed by supervisor)	X	X	X
Approved research protocol with version number and date	X	X	X
Testing instruments	X	X	X
Questionnaires (e.g. diaries, demographics)	X	X	X
Data collection forms	X	X	X
Recruiting, advertising materials, notification letters	X	X	X
Subject information sheets	X	X	X
IRB approved consent document with expiration date/IRB approval stamp	X	X	X
Parental permission (if using children as subjects)	X	X	X
Child assent (if using children as subjects)	X	X	X
Other reviews (Safety, other IRB)	X	X	X
Survey approval (when obtained, usually after IRB approval)	X	X	X
Standards of Conduct/Investigator Assurance	X	X	X
CVs	X	X	N/A
Documents supporting collaboration (approval documents from collaborating institutions)	X	X	X
Command endorsements (if received from sponsor)	X	X	X
Agreements supporting research (MOU, MOA, CRADA, etc.) as applicable	X	X	X
IRB Meeting Minutes	N/A	X	X
Continuing Review Report Submission			
Document approving continuous research	X	X	X
Continuing Review Report	X	X	X
Original signed consent documents for all subjects (if obtained)	X	N/A	N/A
Documented Expedited Review	N/A	X	X
IRB Meeting Minutes	N/A	X	X

	PU File	IRB File	Send DON HRPP
Modification Submission			
Document approving amendment	X	X	X
Amendments to the protocol and/or Informed Consent (change in PI/Associate PI, procedure, population, etc.)	X	X	X
Documented Expedited Review	N/A	X	X
IRB Meeting Minutes	N/A	X	X
Unanticipated Problem/Adverse Event Submission			
Document with results of IRB Review	X	X	X
Adverse Event Report Form	X	X	X
Documented Expedited Review	N/A	X	X
IRB Meeting Minutes	N/A	X	X
Statement of Significant New Findings			
Documents informing subjects	X	X	X
Suspension/Re-instatement			
IRB/Command Review of Suspension	X	X	X
Document Suspending Research	X	X	X
Document Reinstating Research	X	X	X
Document Terminating Research	X	X	X
IRB Meeting Minutes	N/A	X	X
End of Project Report Submission			
Document Approving Final Report	X	X	X
Project Completion Report	X	X	X
Withdrawal Notification	X	X	X
Document Acknowledging Withdrawal	X	X	X
Documented Expedited Review	N/A	X	X
IRB Meeting Minutes	N/A	X	X
Other			
Any other publications, briefings, etc. based on protocol	X	X	N/A

Appendix J: Abbreviations, Acronyms and Initialisms

BLS	Basic Life Support
CFR	Code of Federal Regulations
CITI	Collaborative Institutional Training Initiative
COI	Conflict of Interest
CR	Continuing Review
CRADA	Cooperative Research and Development Agreement
DoD	Department of Defense
DON	Department of Navy
FDA	Food and Drug Administration
FWA	Federal-wide Assurance
HQ	Headquarters
HRPP	Human Research Protection Program
IAIR	Institutional Agreement for IRB Review
IIA	Individual Investigator Agreement
IO	Institutional Official
IPA	Intergovernmental Personnel Act
IRB	Institutional Review Board
NCO	Non-Commissioned Officer
PI	Principal Investigator, Research Personnel
SBIR	Small Business Innovative Research
SECDEF	Secretary of Defense
SG	Surgeon General
SOP	Standard Operating Procedure

SOW.....Statement of Work

UPIRTSO.....Unanticipated Problem Involving Risk to Subjects or Others

Appendix K: Definitions

Adverse Event. Any unfavorable and unintended occurrence associated with the conduct of a research project.

Approval Authority for Research Protocols. Individuals with delegated approval authority that permit research to begin. Such individual also have authority to certify a research protocol.

Associate Investigator. Associate investigators assist the researcher with the design and conduct of a research project or task.

Assurance. See Institutional Assurance.

Assurance Approval Authority. Individuals authorized to approve and renew institutional assurances to DON activities and extramural performers conducting human subjects research, and the authority to accept other DoD or federal assurances.

Certification. The official written notification by the performing institution that a research project or activity involving human subjects has been reviewed and approved by an IRB per an approved assurance. [Reference (b), 32 CFR 219.102(j)]

Collaborator. See Extramural Performer.

Engaged in Research. An activity becomes engaged in research when its personnel or agents either intervene or interact with living individuals for research purposes; or obtain individually identifiable private information for research purposes. [Office for Human Research Protections (formerly OPRR) memo of 26 January 1999]

Extramural Performer. Any individual or organization outside of the Marine Corps that is a party to a contract, grant, interagency transfer, or other agreement with any Navy or Marine Corps activity. An organization includes any Federal, State, municipal, or other Government activity, or any corporation, institution, foundation, agency, or other legal entity, whether foreign or domestic.

Greater Than Minimal Risk. Greater Than Minimal Risk research is defined as any research using human subjects that does not meet the criteria as Minimal Risk.

Headquarters-Level Administrative Review. Administrative review of approved research protocols by DON HRPP to verify regulatory compliance and human research protections following local approval.

Human Subject. A living individual about whom an investigator conducting research obtains either data through intervention or interaction with the individual, or identifiable private information. Intervention includes both physical procedures by which data are gathered and manipulations of the subject or the subject's environment that are performed for research purposes. Interaction includes communication or interpersonal contact between investigator and subject. Identifiable private information is any information from which the identity of the subject associated with the collected data is or may be readily ascertained by the investigator or

associated with the institution. Private information also includes information about behavior that occurs in a context in which an individual can reasonably expect that no observation or recording is taking place, and information which has been provided for specific purposes by an individual and which the individual can reasonably expect will not be made public.

Institutional Assurance. A document originated by an institution and granted by an Assurance Approval Authority authorizing the institution to engage in research supported by the DoD stating that it will comply with federal regulations, DoD, and DON requirements for human subject protections.

Institutional Review Board. The IRB is a committee established in accordance with reference (b) (32 CFR 219), to review research to ensure the protection of the rights and welfare of human research subjects.

Institutional Review Board Member—Naval IRBs. A DON IRB member must be a current federal employee, an individual appointed under the Intergovernmental Personnel Act (IPA), or a consultant consistent with the requirements established by reference (q) (5 USC 3109). Status as a contractor or federal retiree alone is not sufficient to qualify as a federal employee for the purpose of IRB membership.

Institutional Official. A senior IO (the Commander, Commanding Officer, Officer in Charge or Head of Activity) authorized to act for the institution and to assume on behalf of the institution the obligations imposed by the federal regulations, DoD, and DON requirements for the protection of human subjects. The IRB Chair and IRB members may not serve as the IO.

Intramural Performer. Principal Investigator is Marine Corps personnel (military or federal employee of the Marine Corps)

Investigational Test Articles. Drugs, biologicals, and devices defined by U.S. Food and Drug Administration (FDA) as “investigational” because they are not yet approved for public use or commercial distribution. See also “Test Article.”

Minimal Risk. The probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests. The phrase “ordinarily encountered in daily life or during the performance of routine physical or physiological examinations or tests” in the definition of minimal risk shall not be interpreted to include the inherent risks certain categories of human subjects face in their everyday life. For example, the risks imposed in research involving human subjects focused on a special population should not be evaluated against the inherent risks encountered in their work environment (e.g., emergency responder, pilot, soldier in a combat zone) or having a medical condition (e.g., frequent medical tests or constant pain) (reference (d) Paragraph 6.b).

Naval Activities. Refers to both Navy and Marine Corps activities.

Principal Investigator (PI). The Principal Investigator (PI) is the researcher who has the primary responsibility for the design and conduct of a research project or task. In DON-supported human subject research, the PI must be a currently federal employee who possesses

the required education, knowledge, skills, experience (credentials) to initiate, conduct and oversee human subject research, and has completed the required research ethics training including human subject protections. The requirements for both DON-supported Intramural Research and DON-supported Extramural Research are outlined in reference (e).

Prisoner. Any individual (other than Captured or Detained Personnel) involuntarily confined or detained in a penal institution. The term is intended to encompass individuals sentenced to such an institution under a criminal, civil or military statute, individuals detained in other facilities by virtue of statutes or commitment procedures, which provide alternatives to criminal prosecution or incarceration in a penal institution, and individuals detained pending arraignment, trial or sentencing. [Reference (c), 45 CFR 46.303(c)]

Protocol. The detailed written research plan.

Research. Any systematic investigation to include a project, task, test, experiment, development, demonstration, evaluation, or similar undertaking designed to develop or contribute to generalized knowledge. This includes activities where the results are intended for publication, distribution, or use outside of MCCDC, or where the results are to be used in future research activities. Activities that meet this definition constitute research for purposes of this instruction whether or not they are conducted or supported under a program that is considered research for other purposes. For example, some demonstration and service programs may include research activities. [Reference (b), 32 CFR 219.102(d)]

- a. Research includes, but is not limited to, any project, task, test, pilot study, experiment, investigation, study, clinical study, clinical investigation, clinical trial, evaluation, developmental effort or similar undertaking, whether or not conducted or supported under a program that is officially considered research. Any effort, even if not considered research for other purposes, is considered research for purposes of this instruction.
- b. Clarification of FDA-regulated Research: The terms research, clinical research, clinical study, study, and clinical investigation are deemed to be synonymous. Clinical investigation means any experiment that involves a test article and one or more human subjects, and meets the appropriate requirements for prior submission to the Food and Drug Administration. [Excerpted from reference (o) (21 CFR 56.101(c)) and reference (p) (21 CFR 50.3(c))]

Risk. The possibility of harm, discomfort, or injury (physical, psychological, sociological, economic, or other) as a consequence of any act or omission resulting from participation in a research study. Risk can range from minimal to high. Determination of the nature and degree of risk involved in a research project must be determined by the IRB Chair or IRB, not the PI, even if the project is deemed to be "Minimal Risk."

Test Article. Any drug for human use, biological product for human use, medical device for human use, human food additive, color additive, electronic product, or any other article subject to regulation under the act or under sections 351 or 354-360F of the Public Health Service Act. [Reference (o) (21 CFR 56.102(1)) and reference (p) (21 CFR 50.3(j))]